Characterization of Antibiotic-Susceptibility Patterns, Virulence Factor Profiles and Clonal Relatedness in Proteus mirabilis Isolates from Patients with Urinary Tract Infection in Iran

References

• Schaffer JN, Pearson MM. Proteus mirabilis and urinary tract infections. Microbiol Spectr. 2015;3(5). doi:10.1128/microbiolspec.UTI-0017-2013
   PubMedGoogle Scholar
• Armbruster CE, Mobley HL. Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol. 2012;10(11):743–754. doi:10.1038/nrmicro289023042564
   PubMed Web of Science ®Google Scholar
• Armbruster CE, Mobley HL, Pearson MM. Pathogenesis of Proteus mirabilis infection. EcoSal Plus. 2018;8(1). doi:10.1128/ecosalplus.ESP-0009-2017
   PubMedGoogle Scholar
• Luzzaro F, Mezzatesta M, Mugnaioli C, et al. Trends in production of extended-spectrum β-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol. 2006;44(5):1659–1664. doi:10.1128/JCM.44.5.1659-1664.200616672390
   PubMed Web of Science ®Google Scholar
• Nucleo E, Fugazza G, Migliavacca R, et al. Differences in biofilm formation and aggregative adherence between β-lactam susceptible and β-lactamases producing P. mirabilis clinical isolates. New Microbiol. 2010;33(1):37–45.20402412
   PubMed Web of Science ®Google Scholar
• Rocha SP, Elias WP, Cianciarullo AM, et al. Aggregative adherence of uropathogenic Proteus mirabilis to cultured epithelial cells. FEMS Immunol Med Microbiol. 2007;51(2):319–326. doi:10.1111/j.1574-695X.2007.00308.x17714491
   PubMedGoogle Scholar
• Rocha SP, Pelayo JS, Elias WP. Fimbriae of uropathogenic Proteus mirabilis. FEMS Immunol Med Microbiol. 2007;51(1):1–7. doi:10.1111/j.1574-695X.2007.00284.x17640292
   PubMedGoogle Scholar
• Alamuri P, Eaton KA, Himpsl SD, Smith SN, Mobley HL. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection. Infect Immun. 2009;77(2):632–641. doi:10.1128/IAI.01050-0819029299
   PubMed Web of Science ®Google Scholar
• Zanichelli V, Huttner A, Harbarth S, Kronenberg A, Huttner B. Antimicrobial resistance trends in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis urinary isolates from Switzerland: retrospective analysis of data from a national surveillance network over an 8-year period (2009–2016). Swiss Med Wkly. 2019;149:2930.
   Web of Science ®Google Scholar
• Hernandez J, Martinez-Martinez L, Pascual A, Suarez A, Perea E. Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J Antimicrob Chemother. 2000;45(3):407–408. doi:10.1093/jac/45.3.40710702570
   PubMed Web of Science ®Google Scholar
• Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother. 2005;49(7):2598–2605. doi:10.1128/AAC.49.7.2598-2605.200515980325
   PubMed Web of Science ®Google Scholar
• Martínez-Martínez L, Eliecer Cano M, Manuel Rodríguez-Martínez J, et al. Plasmid-mediated quinolone resistance. Expert Rev Anti Infec Ther. 2008;6(5):685–711. doi:10.1586/14787210.6.5.68518847406
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52–59. doi:10.1093/jac/dki16615917288
   PubMed Web of Science ®Google Scholar
• Kanayama A, Kobayashi I, Shibuya K. Distribution and antimicrobial susceptibility profile of extended-spectrum beta-lactamase-producing Proteus mirabilis strains recently isolated in Japan. Int J Antimicrob Agents. 2015;45(2):113–118. doi:10.1016/j.ijantimicag.2014.06.00525182712
   PubMed Web of Science ®Google Scholar
• O’Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;47:1–2.
   Google Scholar
• Mobley HL, Chippendale GR. Hemagglutinin, urease, and hemolysin production by Proteus mirabilis from clinical sources. J Infect Dis. 1990;161(3):525–530. doi:10.1093/infdis/161.3.5252179424
   PubMed Web of Science ®Google Scholar
• Wayne P CLSI. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI Document M100-S25. Clinical and Laboratory Standards Institute; 2015.
   Google Scholar
• Cattoir V, Poirel L, Rotimi V, Soussy C-J, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007;60(2):394–397. doi:10.1093/jac/dkm20417561500
   PubMed Web of Science ®Google Scholar
• Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother. 2009;53(2):639–645. doi:10.1128/AAC.01051-0819064896
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang W, Pan W, et al. Prevalence of qnr, aac (6′)-Ib-cr, qepA, and oqxAB in Escherichia coli isolates from humans, animals, and the environment. Antimicrob Agents Chemother. 2012;56(6):3423–3427. doi:10.1128/AAC.06191-1122391545
   PubMed Web of Science ®Google Scholar
• Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233–2239.7494007
   PubMed Web of Science ®Google Scholar
• Fallah F, Parhiz S, Azimi L. Distribution and antibiotic resistance pattern of bacteria isolated from patients with community-acquired urinary tract infections in Iran: a cross-sectional study. IJHS. 2019;4(2):14–19.
   Google Scholar
• Keyhan H, Sedighi S, Mashayekhi B, Fathi M, Mokhtari M. Community acquired urinary tract infections’ etiological organisms and antibiotics susceptibility patterns. Nephrourol Mon. 2017;9(5). doi:10.5812/numonthly.62146
   Google Scholar
• Mirzarazi M, Rezatofighi SE, Pourmahdi M, Mohajeri MR. Antibiotic resistance of isolated gram negative bacteria from urinary tract infections (UTIs) in Isfahan. Jundishapur J Microbiol. 2013;6(8). doi:10.5812/jjm
   Web of Science ®Google Scholar
• Nasrolahei M, Poorhagibagher M, Vahedi M, Maleki I. Urinary tract infection among intellectual disability individuals” Etiology and antibiotic resistance patterns” in rehabilitation centers of Mazandaran province, Northern Iran. J Prev Med Hyg. 2013;54(3):170–175.24783897
   PubMedGoogle Scholar
• Alves MJ, Barreira J, Carvalho I, et al. Propensity for biofilm formation by clinical isolates from urinary tract infections: developing a multifactorial predictive model to improve the antibiotherapy. J Med Microbiol. 2014;63:471–477. doi:10.1099/jmm.0.071746-024430252
   PubMed Web of Science ®Google Scholar
• Aniejurengho O, Dessi M, Meikle S, Santin M, Okoli I. Biofilm formation in uropathogenic strains of Proteus mirabilis and their susceptibility to poly (epsilon-lysine) dendron. Biosci Res Today World. 2015;1(1):1–9.
   Google Scholar
• Sheykh-Bardsiri H, Shakibaie M, Amini Kafiabad S. Plasmid pattern of biofilm producing Proteus mirabilis and Proteus vulgaris among clinical isolates in Kerman university hospitals during 2011–2012. JKMU. 2013;20(2):146–157.
   Google Scholar
• Mishra M, Thakar Y, Pathak A. Haemagglutination, haemolysin production and serum resistance of proteus and related species isolated from clinical sources. Ind J Med Microbiol. 2001;19(2):5–11.
   Google Scholar
• Sosa V, Schlapp G, Zunino P. Proteus mirabilis isolates of different origins do not show correlation with virulence attributes and can colonize the urinary tract of mice. Microbiol. 2006;152(7):2149–2157. doi:10.1099/mic.0.28846-0
   Web of Science ®Google Scholar
• Zunino P, Sosa V, Schlapp G, Allen AG, Preston A, Maskell DJ. Mannose-resistant Proteus-like and P. mirabilis fimbriae have specific and additive roles in P. mirabilis urinary tract infections. FEMS Immunol Med Microbiol. 2007;51(1):125–133. doi:10.1111/j.1574-695X.2007.00285.x17854474
   PubMedGoogle Scholar
• Mobley HL, Belas R. Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol. 1995;3(7):280–284. doi:10.1016/S0966-842X(00)88945-37551643
   PubMed Web of Science ®Google Scholar
• Jansen AM, Lockatell V, Johnson DE, Mobley HL. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation. Infect Immun. 2004;72(12):7294–7305. doi:10.1128/IAI.72.12.7294-7305.200415557655
   PubMed Web of Science ®Google Scholar
• Ali HH, Yousif MG. Detection of some virulence factors genes of Proteus mirabilis that isolated from urinary tract infection. IJAR. 2015;3(1):156–163.
   Google Scholar
• Stankowska D, Kwinkowski M, Kaca W. Quantification of Proteus mirabilis virulence factors and modulation by acylated homoserine lactones. J Microbiol Immunol Infect. 2008;41(3):243–253.18629420
   PubMedGoogle Scholar
• Magyar A, Köves B, Nagy K, et al. Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. J Med Microbiol. 2017;66(6):788–797. doi:10.1099/jmm.0.00049828621642
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis. 2014;78(4):443–448. doi:10.1016/j.diagmicrobio.2013.11.02524492025
   PubMed Web of Science ®Google Scholar
• Cernohorska L, Chvilova E. Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation. Klin Mikrobiol Infek Lek. 2011;17(3):81–85.
   Google Scholar
• Feglo PK, Gbedema SY, Quay SNA, Adu-Sarkodie Y, Opoku-Okrah C. Occurrence, species distribution and antibiotic resistance of Proteus isolates: a case study at the Komfo Anokye Teaching Hospital (KATH) in Ghana. Int J Pharm Sci Res. 2010;1(9):347–352.
   Google Scholar
• Ahn JY, Ann HW, Jeon Y, et al. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea. BMC Infect Dis. 2017;17(1):327. doi:10.1186/s12879-017-2431-828468622
   PubMed Web of Science ®Google Scholar
• Song W, Kim J, Bae IK, et al. Chromosome-encoded AmpC and CTX-M extended-spectrum β-lactamases in clinical isolates of Proteus mirabilis from Korea. Antimicrob Agents Chemother. 2011;55(4):1414–1419. doi:10.1128/AAC.01835-0921282448
   PubMed Web of Science ®Google Scholar
• Sahal G, Bilkay IS. Multidrug resistance by biofilm-forming clinical strains of Proteus mirabilis. Asian Biomed. 2015;9(4):535–541.
   Web of Science ®Google Scholar
• Subramanian P, Shanmugam N, Sivaraman U, Kumar S, Selvaraj S. Antibiotic resistance pattern of biofilm-forming uropathogens isolated from catheterised patients in Pondicherry, India. Australas Med J. 2012;5(7):344–348. doi:10.4066/AMJ.2012.119322905060
   PubMedGoogle Scholar
• Kwiecińska-Piróg J, Skowron K, Zniszczol K, Gospodarek E. The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms. Biomed Res Int. 2013;2013.
   Web of Science ®Google Scholar
• Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. Microbiol Spectr; 2014;2(5):1–42.
   Google Scholar
• Majlesi A, Kakhki RK, Nejad ASM, et al. Detection of plasmid-mediated quinolone resistance in clinical isolates of Enterobacteriaceae strains in Hamadan, West of Iran. Saudi J Biol Sci. 2018;25(3):426–430. doi:10.1016/j.sjbs.2016.11.01929686506
   PubMed Web of Science ®Google Scholar
• Liang C, Kong Q, Yongmei F, Feng Y, Yang X. Mechanisms of plasmid-mediated quinolone resistance in Proteus mirabilis from urine. J Pract Med. 2017;33(24):4152–4155.
   Google Scholar
• Alabi OS, Mendonça N, Adeleke OE, da Silva GJ. Molecular screening of antibiotic-resistant determinants among multidrug-resistant clinical isolates of Proteus mirabilis from Southwest Nigeria. Afr Health Sci. 2017;17(2):356–365. doi:10.4314/ahs.v17i2.929062330
   PubMed Web of Science ®Google Scholar